About
Michael Gilman, Ph.D. has served as a member of our board of directors since November 2013. Michael Gilman is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Michael Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Michael Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Michael Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Michael Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief
Position in the VCSift Database
- • 2 investors at Arrakis Therapeutics are tracked.
- • 3,360 investors hold the CEO role in VCSift. Michael Gilman is one of them.
- • 2,293 investors are based in Boston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Boston, US
Contact Information
Find more investors like Michael
Search Investors